The inclusion of real world evidence in clinical development planning

Table 2 RWE studies included in the NMA and main data extracted per treatment

Study	Treatments	No. of subjects (N)	No. of Relapses	Person years	EDSS
Lanzillo (2012) [39]	Natalizumab	42	10	42	3.5
Lanzillo (2012) [39]	Rebif 44	42	23	42	3.5
Limmroth (2007) [40]	Avonex	1094	1116	2188	2.62
	Betaferon	1034	1075	2068
	Rebif 22	555	588	1110
	Rebif 44	185	233	370
Halpern (2011) [41]	Natalizumab	288	21	72
	Avonex	151	7	38
	Rebif 22	329	22	82
	Betaferon	144	11	36
	Glatiramer acetate	469	25	117
Patti (2006) [42]	Betaferon	114	137	570	2.2
	Avonex	37	50	185
	Rebif 22	17	35	85
Río (2005) [43]	Placebo	107	288	356	2.73
Río (2005) [43]	Glatiramer acetate	101	204	334	2.73
Haas and Firzlaff (2005) [44]	Avonex	79	109	158	2.2
	Betaferon	77	123	154	2.28
	Glatiramer acetate	79	56	158	1.98
	Glatiramer acetate	48	59	96	2.36
Khan et al. (2001) [45]	Placebo	15	23	23	2.63
	Avonex	34	41	51	2.71
	Betaferon	34	28	51	2.6
	Glatiramer acetate	39	29	59	2.64
Trojano et al. (2003) [46]	Betaferon	209	136	418	2.5
Trojano et al. (2003) [46]	Avonex	169	120	338	2.4
Carra et al. (2003) [47]	Avonex	26	14	35	2.02
	Rebif 44	20	2	27	2.08
	Betaferon	20	11	27	3.31
	Glatiramer acetate	30	8	40	2.45

ISSN: 1745-6215